Segment & Geographic Data Reported Filing Data API & CSV Delivery

Lakeside Holding Ltd's Business Segments

Lakeside Holding Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of Q3 ((Mar 31 2026))
Reportable Segments
-
Per the company's own filing, this quarter
Largest Segment
-
Total Revenue
$ 1
Consolidated, this quarter
Regions Reported
1
Geographic regions, this quarter
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/LSH/segments
https://api.csimarket.com/api/v1/companies/LSH/geographic
https://api.csimarket.com/api/v1/companies/LSH/exposure
Programmatic access for models, analytics, and integration workflows.
Dataset & schema
https://api.csimarket.com/api/datasets/business_segments
https://api.csimarket.com/api/schema/business_segments
https://api.csimarket.com/api/meta/business_segments

Revenue Share by Region - Q3 ((Mar 31 2026))

385%largest
  • Pharmaceutical Distribution China384.6%

Revenue by Geographic Region - Q3 ((Mar 31 2026))

RegionPeriodRevenue
(Millions)
% of Total
Pharmaceutical Distribution ChinaQ3 ((Mar 31 2026))$ 5384.6%

Description of Lakeside Holding Ltd

Lakeside Holding Limited is a U.S.-based company providing integrated cross-border supply chain solutions with a focus on the Asian market, including China and South Korea. The company offers customized cross-border ocean freight and airfreight services in the U.S., supporting the transportation of goods into the country. Its services encompass cross-border freight consolidation and forwarding, customs clearance, warehousing and distribution, and U.S. domestic ground transportation. For the year ended June 30, 2025, Lakeside expanded into pharmaceutical distribution through Hupan Pharmaceutical, a Wuhan-based company offering pharmaceutical distribution and supply chain services. Hupan Pharmaceutical operates in brand promotion and healthcare technology support and collaborates with pharmaceutical manufacturers to supply infusion fluids, which represent its primary products.
The registrant operates a business segment through Hupan Pharmaceutical, a pharmaceutical distribution and supply chain service provider headquartered in Wuhan, China, with divisions in brand promotion and healthcare technology support. The registrant partners with pharmaceutical manufacturers to supply infusion fluids, which constitute the primary pharmaceutical products sold and distributed annually. Additionally, the registrant provides cross-border ocean freight and airfreight solutions in the U.S., customized to customer requirements for transporting goods into the country. The registrant manages three regional warehousing and distribution centers in Illinois and Texas, totaling approximately 142,484 square feet with 52 docks, capable of handling up to 3,000 cubic meters of freight daily. It maintains relationships with over 150 warehouses and distribution terminals across the U.S. to support warehousing and distribution services. As of June 30, 2025, the registrant had fulfilled over 55,000 cross-border supply chain solution orders with an aggregate assessed value of $1.0 billion, including 14,000 orders completed during the year ended June 30, 2025. The registrant also assisted with customs clearance of cross-border freight valued at over $54.0 million as of that date.